Interactions of PPAR α and GLUT4 in DOCA/salt-induced renal injury in mice

Igbe Ighodaro1, Omogbai Kelly Eric, Oyekan Adebayo

  • 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Benin. igbe.ighodaro@uniben.edu.

Insights

In hypertensive kidney injury, glucose transporter type 4 (GLUT4) shows protective effects, especially when peroxisome proliferator activated receptor alpha (PPARα) is activated. This suggests a novel therapeutic target for kidney protection.

Area of Science:

  • Nephrology
  • Metabolic Syndrome
  • Pharmacology

Background:

  • Insulin resistance is linked to hypertension and reduced muscle glucose uptake.
  • Peroxisome proliferator activated receptor alpha (PPARα) activation exacerbates insulin resistance.
  • The interplay between PPARα and glucose transporter type 4 (GLUT4) in hypertensive renal injury is not fully understood.

Purpose of the Study:

  • To investigate the roles of PPARα and GLUT4 in deoxycorticosterone acetate (DOCA)-salt induced hypertensive nephropathy.
  • To evaluate the renoprotective potential of modulating PPARα and GLUT4 pathways.

Main Methods:

  • Utilized wild-type (WT) and PPARα knockout (KO) mice subjected to DOCA-salt treatment.
  • Administered indinavir (GLUT4 antagonist) or fenofibrate (PPARα ligand) to assess their effects.
  • Measured urinary sodium excretion, urine volume, proteinuria, and nitric oxide levels.

Main Results:

  • DOCA/salt treatment increased urinary sodium excretion and urine volume in PPARα KO mice compared to WT.
  • Indinavir exacerbated proteinuria in DOCA/salt-treated PPARα KO mice.
  • Both indinavir and fenofibrate increased urinary sodium excretion and urine volume in DOCA/salt-treated PPARα KO mice.
  • Nitric oxide levels were higher in fenofibrate- and indinavir-treated WT mice compared to KO mice.

Conclusions:

  • GLUT4 appears to play a renoprotective role in hypertensive nephropathy.
  • PPARα activation enhances this protective effect, potentially via increased nitric oxide production.
  • Targeting GLUT4 and PPARα pathways may offer therapeutic strategies for hypertensive kidney disease.

Related Concept Videos